The 2018 National Institute on Aging—Alzheimer’s Association (NIA-AA) research framework proposed a biomarker-based definition of Alzheimer’s disease (AD) reflecting the three core underlying neuropathological processes: amyloid-β (Aβ) deposition, pathologic tau, and neurodegeneration (ATN) (Jack et al., 2018). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.